Clinical trials: Psilocybin
Fibromyalgia
Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action
The purpose of this study is to assess brain activity under Psilocybin in a cohort of people with fibromyalgia.
- Trial name
- Psilopain (NCT05548075)
- Testing
- Psilocybin, Therapeutic support
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Imperial College London
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)
Psilocybin, a serotonin receptor agonist in the brain, significantly and quickly improves depressive symptoms while inducing profound acute subjective effects.
- Trial name
- PSILOTRAZ (NCT07210112)
- Testing
- Psilocybin 25 mg per os, Trazodone 5mg, Trazodone 30 mg
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Centre Hospitalier St Anne
Phantom Limb Pain
Psilocybin-assisted Therapy for Phantom Limb Pain
This double-blind placebo-controlled pilot study seeks to investigate whether psilocybin can be safely administered to people with chronic phantom limb pain (PLP) in a supportive setting with close follow-up, and its effects on…
- Trial name
- NCT05224336
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego
Post-Traumatic Stress Disorder, PTSD
Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD
This is an open-label pilot study designed to evaluate the safety, tolerability, and preliminary clinical effects of psilocybin-enhanced trauma-focused psychotherapy in individuals with post-traumatic stress disorder (PTSD).
- Trial name
- TiPAP-PTSD (NCT07737054)
- Testing
- Psilocybin (drug), Trauma-Focused Psychotherapy
- Where
- Israel
- Volunteers
- 13 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Methamphetamine Use Disorder, Substance-Related Disorders
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD).
- Conditions
- Methamphetamine Use Disorder, Substance-Related Disorders, Chemically-Induced Disorders, Substance Use Disorders
- Trial name
- NCT05322954
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Wisconsin, Madison
Healthy
Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects
Psilocybin is a classic serotonergic hallucinogen acting on the 5-HT2A receptor. It is used recreationally and in psychiatric research.
- Trial name
- NCT03912974
- Testing
- Escitalopram
- Where
- Switzerland
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Healthy Volunteers
Psilocybin Brain Stimulation and Imaging Pilot Study
This open-label pilot psilocybin administration study investigates the influence of psilocybin on brain function and cognitive control functions in clinically and psychiatrically healthy volunteers.
- Trial name
- OPTE (NCT06835699)
- Testing
- Psilocybin 25 mgs, TMS
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Major Depressive Disorder
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
This is an interventional, parallel arm assignment treatment study in individuals with Major Depressive Disorder (MDD). Each individual will be treated with a single dose of pimavanserin or placebo plus a single dose of…
- Trial name
- NCT06592833
- Testing
- Psilocybin, Pimavanserin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Depression
Investigation to Understand and Optimize Psilocybin
This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression.
- Trial name
- OPTIMIZE (NCT06512194)
- Testing
- Psilocybin, Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Charles Raison
Depression, Burnout, Professional
PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout
This project is an open-label randomized study looking at an 8-week Mindfulness-Based Stress Reduction (MBSR) curriculum vs. an 8-week MBSR curriculum + a group psilocybin-assisted psychotherapy intervention for frontline…
- Trial name
- PAPR (NCT05557643)
- Testing
- Psilocybin, Mindfulness-Based Stress Reduction (MBSR)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Utah
Body Dysmorphic Disorders
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin.
- Trial name
- NCT04656301
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New York State Psychiatric Institute
Religious or Spiritual Problem
The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals
The current protocol is a pilot study of the effects and possible utility of psilocybin-facilitated experiences for professional religious leaders.
- Trial name
- NCT02421263
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Anorexia Nervosa
Effects of Psilocybin in Anorexia Nervosa
This open-label pilot study seeks to investigate the safety and efficacy of psilocybin in persons with chronic anorexia nervosa (AN).
- Trial name
- NCT04052568
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Johns Hopkins University
Alcohol Use Disorder
Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder
Twenty participants, age 18 or older, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for moderate to severe Alcohol Use Disorder will be randomized to open-label psilocybin (25 mg) therapy with…
- Trial name
- NCT04410913
- Testing
- Psilocybin plus Visual Healing Set and Setting, Psilocybin plus Standard Set and Setting
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Keith Heinzerling
Healthy
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects
4-bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive substance with reportedly similar acute effects to both the prototypical empathogen 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and the classic psychedelic…
- Trial name
- 2C-B (NCT05523401)
- Testing
- 4-bromo-2,5-dimethoxyphenethylamine (10 mg), 4-bromo-2,5-dimethoxyphenethylamine (20 mg), 4-bromo-2,5-dimethoxyphenethylamine (30 mg)
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Irritable Bowel Syndrome
Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
Participants with IBS (all subtypes) and with no exclusionary comorbid psychiatric or medical disorders will be enrolled in the study.
- Trial name
- NCT06206265
- Testing
- TRYP-0082, Psychotherapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- TRYP Therapeutics
Treatment-resistant Depression
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
The study aims to investigate the safety and efficacy of oral psilocybin administered under supportive conditions in treatment-resistant major depression (TRD).
- Trial name
- EPIsoDE (NCT04670081)
- Testing
- Psilocybin, Nicotinamide
- Where
- 2 sites in Germany
- Volunteers
- 144 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Posttraumatic Stress Disorder
Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)
The purpose of this study is to assess the safety and effectiveness of co-administered MDMA and psilocybin in military Veterans with a diagnosis of Posttraumatic Stress Disorder (PTSD).
- Trial name
- PAM-VET (NCT06989957)
- Testing
- Psilocybin, MDMA
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Severe Alcohol Use Disorder
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial
- Trial name
- NCT06160232
- Testing
- Psilocybin (high dose)
- Where
- Belgium
- Volunteers
- 62 people
- Sponsor
- Brugmann University Hospital
Chronic Low-back Pain, Depression
Psilocybin in Chronic Low Back Pain and Depression
This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain among patients with co-morbid chronic low back pain and depression (CLBP+D).
- Trial name
- NCT06355414
- Testing
- Psilocybin, Methylphenidate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University